Kurs & Likviditet
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2020-11-20 09:54:29
Gentian Diagnostics AS is pleased to announce that the results from a study
conducted in collaboration with Charité - Universitätsmedizin Berlin and Labor
Berlin have been published in the Letter to the Editor in the scientific journal
"Journal of Infection".
The study has evaluated the performance of calprotectin in prediction of severe
events e.g. admission to intensive care unit (ICU), multiorgan failure (MOF) and
mortality in COVID-19 patients presented at the Emergency Department (ED).
66 patients presented to the ED with suspected Sars-CoV-2 infection were
prospectively enrolled in the study. Using PCR testing in pharyngeal swabs, 47
patients tested as negative, and 19 patients were diagnosed with COVID-19. The
performance of calprotectin was compared with the performance of routinely used
biomarkers: lactate, C-reactive protein (CRP) and procalcitonin (PCT).
The study results show high performance of calprotectin in prediction of MOF and
admission to the ICU, and it also suggests calprotectin as a valuable biomarker
for early management in COVID-19 patients evaluated in the ED. The authors
conclude that the data strongly argue that calprotectin might represent an
addition to the biomarker repertoire in the ED, since it seems to perform better
than traditional biomarkers.
The conclusion from this study supports calprotectin as a novel and useful
discriminator in COVID-19 patients admitted to the ED, with respect to disease
outcome, e.g. MOF and ICU admission, and calprotectin measurement in blood
samples being easily applicable in routine laboratories.
Several recent studies have reported increased levels of calprotectin in
patients with severe SARS-Cov-2 infection, as well as the possibility of
calprotectin to differentiate between mild and severe forms of the disease, and
its ability to predict the need for mechanical ventilation and mortality.
Please see the enclosed press release for additional information.
For further information, please contact:
Hilja Ibert CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242
Njaal Kind CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone: +47 919 06 525